BioNTech (BNTX) Shares Plunge 8% Following Colorectal Cancer Vaccine Trial Discontinuation

BioNTech (BNTX) shares dropped 8% after discontinuing its Phase 2 mRNA colorectal cancer vaccine trial due to futility and survival imbalances.

The post BioNTech (BNTX) Shares Plunge 8% Following Colorectal Cancer Vaccine Trial Discontinuation appeared first on Blockonomi.